Purple Style Labs Limited’s ₹680.00 crore IPO entered its final day of public subscription today, September 2, 2026, with a price band of ₹546 to ₹575 per share. As of 10:45 A.M on the third day of bidding, the issue had been subscribed 0.27 times.
The basis of allotment is expected to be finalised on September 3, 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on September 7, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
31 August 2026 |
|
Subscription Closing Date |
2 September 2026 |
|
Basis of Allotment Date |
3 September 2026 |
|
Refund Initiation Date |
4 September 2026 |
|
Credit of Shares |
4 September 2026 |
|
Listing on BSE and NSE |
7 September 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[September 2, 2026, 10:40 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.06x |
|
Non-Institutional Investors (NIIs) |
0.15x |
|
Retail Individual Investors (RIIs) |
1.11x |
|
Total |
0.27x |
The company intends to utilise the net proceeds from the fresh issue towards:
Purple Style Labs Limited is an omni-channel luxury fashion company and the parent of Pernia's Pop-Up Shop, a multi-brand platform for designer fashion in India. Incorporated in 2015, it retails luxury apparel, jewellery, and accessories through its website, mobile app, experience centres, and curated fashion events.
As of March 31, 2026, the platform featured products from 1,109 active designer brands across womenswear, menswear, kidswear, jewellery, and accessories, with a strong focus on wedding and occasion wear.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
557.83 |
489.90 |
504.37 |
|
EBITDA |
30.37 |
41.98 |
31.63 |
|
Profit After Tax (PAT) |
(285.39) |
(188.38) |
(47.71) |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here